Current Partnering Opportunities
Biosurgery
EvitarTM (TTX-333) - Prevention of Tissue Fibrosis Formation following abdominal/pelvic surgery (Phase 2B/3):
- Markets available: US, EU, & ROW, including Japan, China, S. Korea, ASEAN, Australia, India, MENA, CIS and LATAM for EvitarTM.
- The first drug shown in clinical trials to prevent tissue fibrosis formation following laparoscopic surgery.
- Partnership sought: R&D Collaboration with Option to License at NDA/MAA Approval
Endometriosis
TTX-334Dx-Non-invasive blood test for diagnosing endometriosis (entering Phase 2 trials)
- Collaboration with EndoDiag (Paris, France)
- Temple/EndoDiag will conduct clinical work and regulatory filings
- Partnership sought: R&D Collaboration with option to license at approval (510K-CE-IVD)
TTX-334e-Drug candidate with novel MoA-non-hormonal therapy for Endometriosis
- Temple will conduct preclinical and clinical work in conjunction with partner
- Worldwide markets available
- Partnership sought: R&D Collaboration with option to license at NDA/MAA approval
Oncology
TTX-335o-Novel targeted therapy for recurrent, sensitive and platinum resistant ovarian cancers (Preclinical)
- Worldwide markets available
- Data generated for recurrent, sensitive and platinum resistant ovarian cancer cells
- Won prestigious EU Eurostars Grant in 2019 ($3M)
- Data available in other cancers which can also be developed in conjunction with partner
- Partnership sought: Option to license at IND or Phase 1 (build to buy)
Our medical advisors, collaborators and researchers work at the following organizations.
